Abetalipoproteinemia, also known as Bassen-Kornzweig syndrome, is a rare genetic disorder that disrupts the normal absorption of fats, cholesterol, and fat-soluble vitamins in the intestines. This condition leads to various progressive symptoms that primarily affect crucial bodily functions such as vision, blood flow, and the nervous and gastrointestinal systems. Fortunately, early detection and appropriate medical intervention can effectively manage the progression of abetalipoproteinemia and enhance the overall prognosis.
Cause
Abetalipoproteinemia occurs as a consequence of genetic mutations in the MTTP gene. This gene is responsible for producing MTP proteins, which play a crucial role in the formation of beta-lipoproteins. These beta-lipoproteins are responsible for transporting cholesterol, fats, and fat-soluble vitamins from the intestines to various tissues in the body through the bloodstream. However, the presence of mutations in the MTTP gene disrupts the production of MTP proteins, resulting in the body’s inability to transport these essential nutrients. Consequently, deficiencies in these nutrients begin to develop, ultimately leading to various health problems.
History
Abetalipoproteinemia, also known as Bassen-Kornzweig syndrome, was first reported by Doctors Bassen and Kornzweig in 1950. In 1960, H. B. Salt discovered the absence of serum beta-lipoprotein in a patient, leading to the condition being named abetalipoproteinemia. Over the years, more specialists have studied individuals with the condition, uncovering valuable insights into its functioning. Through further research and discovery, the genetic cause of abetalipoproteinemia has been revealed.